Amir Nashat is a Managing Partner in Polaris’ Boston office. He joined Polaris in 2002 and focuses on investments in healthcare, consumer products and energy.
Amir currently represents Polaris as a Director of AgBiome, aTyr Pharmaceuticals, BIND Therapeutics (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Promedior Pharmaceuticals, Scholar Rock, and Selecta Biosciences. Additionally, Amir has served as a Director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals), Receptos (NASDAQ: RCPT), Sun Catalytix (acquired by Lockheed Martin) and served as a Board Observer of GI Dynamics (GID.AX). In addition to his role as an investor, Amir has also served as the initial CEO of Living Proof and Sun Catalytix Corporation.
Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. He previously served on the Board of the New England Venture Capital Association. He has been named to the Forbes Midas list of Top 100 Venture Capitalists.
Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.